GeneDx (WGS) Stock Price, News & Analysis

Company Overview

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

Key Stats

• Today's Range: $94.00 to $106.73
• 50-Day Range: $59.54 to $112.76
• 52-Week Range: $7.72 to $115.60
• Volume: 1.28 million shs
• Average Volume: 592,859 shs
• Market Capitalization: $2.65 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $72.33
• Consensus Rating: Moderate Buy

GeneDx Stock Analysis - MarketRank™

GeneDx scored higher than 38% of companies evaluated by MarketBeat, and ranked 741st out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

GeneDx has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 115.46%

Earnings Growth

Earnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeneDx is -48.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeneDx is -48.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GeneDx has a P/B Ratio of 10.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.39% of the float of GeneDx has been sold short.

Short Interest Ratio / Days to Cover

GeneDx has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeneDx has recently increased by 28.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeneDx does not currently pay a dividend.

Dividend Growth

GeneDx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.39% of the float of GeneDx has been sold short.

Short Interest Ratio / Days to Cover

GeneDx has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeneDx has recently increased by 28.50%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.38

News Sentiment

GeneDx has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for GeneDx this week, compared to 6 articles on an average week.

Search Interest

Only 11 people have searched for WGS on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

MarketBeat Follows

10 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,315,903.00 in company stock.

Percentage Held by Insiders

27.30% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

WGS Stock Analysis - Frequently Asked Questions

How have WGS shares performed this year?

GeneDx's stock was trading at $76.86 at the beginning of 2025. Since then, WGS shares have increased by 22.8% and is now trading at $94.35.
View the best growth stocks for 2025 here.

How were GeneDx's earnings last quarter?

GeneDx Holdings Corp. (NASDAQ:WGS) posted its earnings results on Tuesday, February, 18th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.04 by $0.66. The business earned $95.64 million during the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive trailing twelve-month return on equity of 3.33%.

When did GeneDx's stock split?

GeneDx's stock reverse split before market open on Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are GeneDx's major shareholders?

GeneDx's top institutional investors include Oracle Investment Management Inc. (3.73%), Vanguard Group Inc. (3.66%), Summit Partners Public Asset Management LLC (2.75%) and William Blair Investment Management LLC (2.44%). Insiders that own company stock include Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Tactical Opportunit Blackstone, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Jason Ryan, Daniel Emmett Clark, Isaac Ro, Eric Schadt, Karen Ann White, Katherine Stueland, Kevin Feeley, Shawn Assad, Richard Miao and Anthony Prentice.
View institutional ownership trends.

How do I buy shares of GeneDx?

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GeneDx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 2/18/2025
• Today: 3/03/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:WGS
• CIK: 1818331
• Web: sema4.com
• Phone: 800-298-6470
• Fax: N/A
• Employees: 1,200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $72.33
• High Stock Price Target: $118.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: -23.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 97.27
• P/E Growth: N/A
• Net Income: $-175,770,000.00
• Net Margins: -17.12%
• Pretax Margin: -31.52%
• Return on Equity: 3.33%
• Return on Assets: 1.69%

Debt

• Debt-to-Equity Ratio: 0.25
• Current Ratio: 2.40
• Quick Ratio: 2.27

Sales & Book Value

• Annual Sales: $305.45 million
• Price / Sales: 8.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.78 per share
• Price / Book: 10.75

Miscellaneous

• Outstanding Shares: 28,068,000
• Free Float: 19,971,000
• Market Cap: $2.65 billion
• Optionable: Optionable
• Beta: 2.01